Pioneer Group reinvests in NuVision

Pioneer Group has reinvested in Nottingham-based company NuVision to help accelerate its first two products – designed to aid the healing of eye conditions – before a Series A round in the next 12 months.

NuVision’s wound dressings are manufactured from the amniotic membrane, the sac that surrounds

Students at Anglia Ruskin University (ARU) have been working with Diabetes UK to find solutions for people living with type 1 diabetes.

The partnership is part of the university’s Students at the Heart of Knowledge Exchange (SHoKE) project, which has previously seen ARU students work with public sector organisations across Essex and Cambridgeshire to find tangible solutions to issues faced by residents.

Type 1 diabetes is a condition where the pancreas cannot produce a hormone called insulin to regulate blood sugar levels.

The latest part of the SHoKE project saw teams of students develop ideas to help those students living with type 1 diabetes make the transition from home to university, with four themes selected by the charity for further development: empathy and reducing stigma around diabetes; peer mentoring; a diabetes app; and a student information pack.

Students presented their work to Chris Askew, CEO of Diabetes UK, at an online event, and the projects were showcased in poster format at an exhibition at ARU’s Cambridge campus in March.

Trudy Lynch, SHoKE partnership facilitator at Anglia Ruskin University (ARU), said:

“This collaboration with Diabetes UK has given our students an opportunity to apply their skills and exchange knowledge to develop some excellent ideas and understand the challenges facing those living with diabetes.

“Their proposals focus on contributing to the health and social wellbeing of young people and I hope they can be taken forward by Diabetes UK to bring benefit to everyone.” babies in the womb, and are used to aid the regeneration and healing of the eye’s surface. Its first product, Omnigen, is already approved for treatment on the NHS and is used in hospitals and private clinics in the UK and overseas.

Omnigen may be applied in the operating theatre or, when used in combination with the company’s bespoke bandage contact lens, OmniLenz, in the outpatient department or clinic.

Andy Hill, CEO of NuVision, said: “We are delighted to receive further support from our existing investors. This investment round is an endorsement of our innovative new therapies for ocular care and our commitment to developing rapid and accessible treatment for ocular injury. The next stage of development is the scaling of our commercial and operational capabilities ahead of a planned Series A round in late 2023 or early 2024.”